BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• Press Releases

  Neurogen Biomarking to present novel data on at-home p-tau 217 testing for Alzheimer’s disease at Alzheimer’s Association International Conference® 2025

  July 17, 2025

   · 

  1 min read
• Press Releases

  Instem Announces Provantis® 12: A Powerful Step Forward in Preclinical Study Management

  July 17, 2025

   · 

  3 min read
• Press Releases

  Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU)

  July 17, 2025

   · 

  5 min read
• Press Releases

  Maxwell Biosciences Announces AI Department & Hiring of Jon McClure

  New leadership to spearhead AI-driven breakthroughs in drug discovery and operational excellence

  July 17, 2025

   · 

  4 min read
• Press Releases

  Hairy Cell Leukemia Market to Surpass USD 223.3 Million in 2032, Driven by Rising Cases of Rare Hematologic Cancers | Coherent Market Insights

  July 17, 2025

   · 

  1 min read
• Press Releases

  NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

  Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial Results

  July 17, 2025

   · 

  7 min read
• 

  Layoffs

  Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic

  Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant pipeline shift and adding a black box warning to its Duchenne muscular dystrophy gene therapy Elevidys.

  July 17, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Drug Pricing

  BMS, Pfizer Join DTC Trend, Offering Eliquis to Patients for 40% Below List Price

  In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer pitched the direct-to-consumer program as a way to allow uninsured, underinsured and self-pay patients to pay less out of pocket.

  July 17, 2025

   · 

  2 min read

   · 

  Nick Paul Taylor
• Press Releases

  Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

  July 17, 2025

   · 

  6 min read
• Press Releases

  Exactech Appoints New Chief Medical Officer

  July 17, 2025

   · 

  3 min read